NASDAQ:EXAS - Exact Sciences Stock Price Target and Predictions

Target and Analyst Ratings
Price Target History
Upgrades and Downgrades
News Sentiment
About
FAQ

Consensus Rating: Buy
Consensus Price Target: $71.00
Forecasted Upside: 67.61 %
Number of Analysts: 11
Breakdown:
0 Sell Ratings
3 Hold Ratings
8 Buy Ratings
0 Strong Buy Ratings

^$42.36 As of 08/11/2022 01:00 AM ET

▼ -2.77 (-6.14%)

1 month | 3 months | 12 months

Get New Exact Sciences Analyst Ratings Delivered To Your Inbox

Sign-up to receive the latest news and ratings for EXAS and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for EXAS

^$71.00

▲ +67.61% Upside Potential

This price target is based on 11 analysts offering 12 month price targets for Exact Sciences in the last 3 months. The average price target is $71.00, with a high forecast of $130.00 and a low forecast of $50.00. The average price target represents a 67.61% upside from the last price of $42.36.

Current Consensus is Buy

The current consensus among 11 polled investment analysts is to buy stock in Exact Sciences. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

0 strong buy ratings
10 buy ratings
3 hold ratings
0 sell ratings

Ratings as of

2/17/2021

0 strong buy ratings
9 buy ratings
3 hold ratings
0 sell ratings

Ratings as of

5/18/2021

0 strong buy ratings
11 buy ratings
3 hold ratings
0 sell ratings

Ratings as of

8/16/2021

0 strong buy ratings
10 buy ratings
1 hold ratings
0 sell ratings

Ratings as of

11/14/2021

0 strong buy ratings
10 buy ratings
1 hold ratings
0 sell ratings

Ratings as of

2/12/2022

0 strong buy ratings
9 buy ratings
2 hold ratings
0 sell ratings

Ratings as of

5/13/2022

0 strong buy ratings
9 buy ratings
3 hold ratings
0 sell ratings

Ratings as of

7/12/2022

0 strong buy ratings
8 buy ratings
3 hold ratings
0 sell ratings

Ratings as of

8/11/2022

Latest Recommendations

Show Most Recent Rating from Each Ratings Firm Show All Ratings

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price
8/9/2022	Evercore ISI	Boost Price Target		$65.00	N/A
8/9/2022	Benchmark	Lower Price Target		$54.00	N/A
8/3/2022	Raymond James	Lower Price Target	Outperform	$80.00 ➝ $70.00	Low
8/3/2022	Citigroup	Lower Price Target	Neutral	$65.00 ➝ $50.00	Low
8/3/2022	Robert W. Baird	Lower Price Target	Outperform	$90.00 ➝ $75.00	Low
8/3/2022	BTIG Research	Lower Price Target	Buy	$100.00 ➝ $70.00	Low
8/3/2022	Cowen	Lower Price Target	Outperform	$83.00 ➝ $67.00	N/A
8/3/2022	Cowen	Lower Price Target	Outperform	$83.00 ➝ $67.00	Low
8/3/2022	Craig Hallum	Lower Price Target	Buy	$81.00 ➝ $60.00	Low
7/19/2022	Cowen	Set Price Target		$83.00	Low
6/2/2022	Piper Sandler	Initiated Coverage	Neutral	$50.00	High
4/27/2022	Craig Hallum	Lower Price Target		$100.00 ➝ $81.00	Low
4/27/2022	Robert W. Baird	Lower Price Target		$100.00 ➝ $90.00	High
4/27/2022	Raymond James	Lower Price Target		$90.00 ➝ $80.00	High
4/27/2022	Citigroup	Lower Price Target		$80.00 ➝ $65.00	High
4/19/2022	The Goldman Sachs Group	Lower Price Target	Buy	$100.00 ➝ $85.00	Low
2/23/2022	Craig Hallum	Lower Price Target		$133.00 ➝ $100.00	High
2/23/2022	Raymond James	Lower Price Target	Outperform	$130.00 ➝ $90.00	High
2/23/2022	Wells Fargo & Company	Lower Price Target	Equal Weight	$95.00 ➝ $80.00	High
2/23/2022	Robert W. Baird	Lower Price Target		$116.00 ➝ $100.00	High
2/23/2022	Citigroup	Lower Price Target	Neutral	$100.00 ➝ $80.00	High
2/23/2022	SVB Leerink	Lower Price Target	Outperform	$140.00 ➝ $130.00	High
11/3/2021	BTIG Research	Lower Price Target	Positive ➝ Buy	$145.00 ➝ $120.00	High
11/3/2021	Craig Hallum	Lower Price Target	Buy	$144.00 ➝ $133.00	High
11/3/2021	SVB Leerink	Lower Price Target	Outperform	$160.00 ➝ $140.00	High
11/3/2021	Wells Fargo & Company	Lower Price Target	Equal Weight	$120.00 ➝ $95.00	High
11/3/2021	Robert W. Baird	Lower Price Target	Outperform	$125.00 ➝ $116.00	High
11/3/2021	Raymond James	Downgrade	Strong-Buy ➝ Outperform	$160.00 ➝ $130.00	High
10/14/2021	Cowen	Lower Price Target	Outperform	$160.00 ➝ $135.00	Low
7/29/2021	Stifel Nicolaus	Lower Price Target	Buy	$165.00 ➝ $145.00	High
7/29/2021	BTIG Research	Lower Price Target	Buy	$155.00 ➝ $145.00	High
7/29/2021	Oppenheimer	Lower Price Target	Outperform	$161.00 ➝ $155.00	High
7/29/2021	Robert W. Baird	Lower Price Target	Outperform	$157.00 ➝ $127.00	High
7/14/2021	SVB Leerink	Lower Price Target	Outperform	$170.00 ➝ $160.00	High
6/21/2021	Wells Fargo & Company	Boost Price Target	Equal Weight	$115.00 ➝ $120.00	Low
6/15/2021	Raymond James	Initiated Coverage	Strong-Buy	$160.00	Medium
6/3/2021	The Goldman Sachs Group	Initiated Coverage	Buy	$160.00	Low
5/25/2021	Wells Fargo & Company	Initiated Coverage	Equal Weight	$115.00	Low
5/12/2021	Truist Financial	Lower Price Target	Buy	$226.00 ➝ $168.00	Medium
5/5/2021	Craig Hallum	Lower Price Target	Buy	$161.00 ➝ $144.00	High
5/5/2021	BTIG Research	Lower Price Target	Buy	$175.00 ➝ $155.00	High
5/5/2021	SVB Leerink	Lower Price Target	Outperform	$180.00 ➝ $170.00	High
2/18/2021	Robert W. Baird	Lower Price Target	Outperform	$169.00 ➝ $163.00	Low
2/17/2021	Stifel Nicolaus	Boost Price Target	Buy	$150.00 ➝ $165.00	Low
2/17/2021	SVB Leerink	Boost Price Target	Market Perform ➝ Outperform	$170.00 ➝ $180.00	Low
2/17/2021	Cowen	Boost Price Target	Outperform	$154.00 ➝ $180.00	Low
1/27/2021	Truist Financial	Initiated Coverage	Buy	$226.00 ➝ $226.00	Medium
1/21/2021	SVB Leerink	Boost Price Target	Outperform	$160.00 ➝ $170.00	Medium
10/29/2020	UBS Group	Downgrade	Buy ➝ Neutral	$125.00 ➝ $140.00	High
10/28/2020	Oppenheimer	Boost Price Target		$115.00 ➝ $150.00	Low
10/28/2020	BTIG Research	Boost Price Target		$140.00 ➝ $155.00	Low
10/28/2020	Smith Barney Citigroup	Downgrade	Buy ➝ Neutral	$120.00 ➝ $140.00	Low
10/28/2020	Robert W. Baird	Boost Price Target	Positive ➝ Outperform	$135.00 ➝ $150.00	Low
10/28/2020	SVB Leerink	Boost Price Target	Outperform	$115.00 ➝ $160.00	Low
10/28/2020	Benchmark	Boost Price Target	Buy	$110.00 ➝ $145.00	Low
7/31/2020	SVB Leerink	Boost Price Target	Outperform	$90.00 ➝ $115.00	High
7/31/2020	Benchmark	Boost Price Target	Buy	$90.00 ➝ $110.00	Low
7/31/2020	Citigroup	Boost Price Target	Buy	$110.00 ➝ $120.00	Low
7/8/2020	Oppenheimer	Reiterated Rating	Buy		High
6/25/2020	Citigroup	Boost Price Target	Buy	$100.00 ➝ $110.00	Medium
5/7/2020	Robert W. Baird	Boost Price Target	Outperform	$90.00 ➝ $92.00	Low
5/7/2020	Bank of America	Boost Price Target	Buy	$88.00 ➝ $94.00	Low
5/7/2020	Craig Hallum	Lower Price Target	In-Line ➝ Buy	$99.00 ➝ $92.00	Low
5/7/2020	SVB Leerink	Lower Price Target	Outperform	$100.00 ➝ $90.00	High
4/28/2020	UBS Group	Lower Price Target	Buy	$135.00 ➝ $115.00	High
4/22/2020	Citigroup	Lower Price Target	Buy	$120.00 ➝ $100.00	Medium
4/22/2020	Robert W. Baird	Lower Price Target	Outperform	$100.00 ➝ $90.00	High
4/21/2020	Oppenheimer	Reiterated Rating	Buy	$115.00	Low
4/17/2020	Craig Hallum	Lower Price Target	Buy	$127.00 ➝ $99.00	High
4/2/2020	Stifel Nicolaus	Lower Price Target	Buy	$110.00 ➝ $90.00	Low
4/2/2020	Evercore ISI	Initiated Coverage	Outperform	$70.00	High
2/14/2020	Stifel Nicolaus	Reiterated Rating	Buy	$110.00	N/A
2/12/2020	Robert W. Baird	Reiterated Rating	Buy		Low
1/10/2020	BTIG Research	Initiated Coverage	Buy	$127.00	High
1/6/2020	Citigroup	Initiated Coverage	Buy	$120.00	Low
12/13/2019	Dougherty & Co	Initiated Coverage	Buy	$120.00	Low
11/14/2019	Stifel Nicolaus	Initiated Coverage	Buy	$110.00	High
10/31/2019	Bank of America	Reiterated Rating	Buy	$135.00	Medium
10/30/2019	SVB Leerink	Lower Price Target	Outperform	$133.00 ➝ $105.00	Medium
10/30/2019	Jefferies Financial Group	Lower Price Target	Buy	$138.00 ➝ $120.00	High
10/17/2019	Bank of America	Boost Price Target	Buy	$130.00 ➝ $135.00	Low
9/26/2019	Oppenheimer	Initiated Coverage	Outperform	$130.00	Medium
9/24/2019	SVB Leerink	Reiterated Rating	Buy		High
9/23/2019	Benchmark	Upgrade	Hold ➝ Buy	$130.00	High
9/10/2019	William Blair	Reiterated Rating	Buy		Low
8/1/2019	UBS Group	Boost Price Target	Buy	$120.00 ➝ $143.00	Low
7/30/2019	Craig Hallum	Boost Price Target	Buy	$115.00 ➝ $127.00	Medium
7/29/2019	Cowen	Boost Price Target	Outperform	$125.00 ➝ $135.00	Low
5/1/2019	Jefferies Financial Group	Boost Price Target	Buy	$100.00 ➝ $115.00	Low
5/1/2019	UBS Group	Boost Price Target	Buy ➝ Buy	$115.00 ➝ $120.00	Low
5/1/2019	Craig Hallum	Reiterated Rating	Buy	$95.00 ➝ $115.00	Low
5/1/2019	BTIG Research	Boost Price Target	Buy	$130.00	Low
4/16/2019	UBS Group	Boost Price Target	Buy ➝ Buy	$109.00 ➝ $115.00	Low
2/26/2019	The Goldman Sachs Group	Upgrade	Neutral ➝ Buy	$85.00 ➝ $120.00	Medium
2/22/2019	UBS Group	Set Price Target	Buy	$109.00	Low
2/22/2019	Craig Hallum	Set Price Target	In-Line ➝ Buy	$77.00 ➝ $95.00	High
2/22/2019	BTIG Research	Boost Price Target	Buy ➝ Positive	$110.00	High
2/21/2019	Robert W. Baird	Boost Price Target	Outperform	$90.00 ➝ $102.00	High
1/28/2019	UBS Group	Boost Price Target	Buy	$100.00 ➝ $109.00	Medium
1/7/2019	William Blair	Reiterated Rating	Outperform		High
11/29/2018	UBS Group	Set Price Target	Buy	$100.00	Low
10/31/2018	Jefferies Financial Group	Boost Price Target	Buy ➝ Buy	$74.00 ➝ $84.00	Low
10/30/2018	UBS Group	Set Price Target	Buy	$100.00	High
10/9/2018	UBS Group	Initiated Coverage	Buy ➝ Buy	$100.00	Low
9/11/2018	Robert W. Baird	Boost Price Target	Outperform ➝ Outperform	$74.00 ➝ $85.00	Low
9/6/2018	Bank of America	Boost Price Target	Buy ➝ Buy	$68.00 ➝ $92.00	Medium
9/5/2018	Cowen	Boost Price Target	Outperform	$65.00 ➝ $100.00	High
9/5/2018	Benchmark	Reiterated Rating	Hold ➝ Hold		High
8/30/2018	The Goldman Sachs Group	Boost Price Target	Neutral	$75.00	Low
8/23/2018	Craig Hallum	Boost Price Target	Buy	$54.00 ➝ $74.00	Medium
8/23/2018	Jefferies Financial Group	Reiterated Rating	Buy	$74.00	High
8/23/2018	SVB Leerink	Reiterated Rating	Outperform	$90.00	High
8/23/2018	Robert W. Baird	Boost Price Target	Outperform ➝ Outperform	$65.00 ➝ $74.00	High
8/22/2018	BTIG Research	Boost Price Target	Buy	$95.00	High
8/2/2018	Jefferies Financial Group	Lower Price Target	Buy ➝ Buy	$60.00 ➝ $57.00	High
8/2/2018	Bank of America	Lower Price Target	Buy ➝ Buy	$75.00 ➝ $68.00	High
8/2/2018	Craig Hallum	Lower Price Target	Buy	$60.00 ➝ $54.00	High
7/23/2018	Bank of America	Boost Price Target	Buy ➝ Buy	$67.00 ➝ $75.00	Medium
7/18/2018	SVB Leerink	Reiterated Rating	Outperform ➝ Outperform	$67.00 ➝ $76.00	Low
7/9/2018	Robert W. Baird	Boost Price Target	Outperform ➝ Outperform	$66.00 ➝ $70.00	Low
6/18/2018	Cowen	Boost Price Target	Outperform	$65.00 ➝ $85.00	Low
6/5/2018	Robert W. Baird	Boost Price Target	Outperform ➝ Outperform	$58.00 ➝ $66.00	Medium
6/5/2018	BTIG Research	Reiterated Rating	Buy		Medium
5/30/2018	BTIG Research	Boost Price Target	Positive ➝ Buy	$60.00 ➝ $70.00	High
4/29/2018	BTIG Research	Reiterated Rating	Buy	$60.00	High
4/3/2018	BTIG Research	Upgrade	Neutral ➝ Buy		Low
3/29/2018	William Blair	Reiterated Rating	Buy		N/A
3/28/2018	SVB Leerink	Set Price Target	Buy	$67.00	High
2/27/2018	Robert W. Baird	Upgrade	Neutral ➝ Outperform	$42.56 ➝ $56.00	Medium
2/23/2018	SVB Leerink	Set Price Target	Buy	$67.00	High
2/23/2018	Benchmark	Downgrade	Buy ➝ Hold		High
2/9/2018	SVB Leerink	Set Price Target	Buy	$67.00	Medium
1/29/2018	The Goldman Sachs Group	Initiated Coverage	Neutral ➝ Neutral	$17.77 ➝ $51.00	Low
1/17/2018	Benchmark	Set Price Target	Buy	$65.00	Medium
1/10/2018	William Blair	Reiterated Rating	Buy		High
1/8/2018	Bank of America	Set Price Target	Buy	$67.00	High
1/2/2018	William Blair	Reiterated Rating	Buy		Low
11/29/2017	Bank of America	Boost Price Target	Buy	$58.00 ➝ $67.00	Low
11/13/2017	SVB Leerink	Reiterated Rating	Outperform	$63.00 ➝ $67.00	N/A
11/13/2017	Robert W. Baird	Downgrade	Outperform ➝ Neutral	$56.00	N/A
11/1/2017	BTIG Research	Downgrade	Buy ➝ Neutral		N/A
10/31/2017	Bank of America	Boost Price Target	Buy	$56.00 ➝ $58.00	N/A
10/31/2017	Robert W. Baird	Boost Price Target	Outperform	$49.00 ➝ $56.00	N/A
10/31/2017	Craig Hallum	Boost Price Target	Buy	$46.00 ➝ $61.00	N/A
10/31/2017	Benchmark	Reiterated Rating	Buy ➝ Buy	$50.00 ➝ $60.00	N/A
10/31/2017	SVB Leerink	Reiterated Rating	Outperform	$50.00 ➝ $63.00	N/A
10/31/2017	Jefferies Financial Group	Boost Price Target	Buy	$60.00	N/A
10/19/2017	Bank of America	Set Price Target	Buy	$40.00 ➝ $56.00	N/A
10/6/2017	Robert W. Baird	Reiterated Rating	Buy	$49.00	N/A
9/21/2017	SVB Leerink	Reiterated Rating	Outperform ➝ Outperform	$45.00 ➝ $50.00	High
8/24/2017	SVB Leerink	Set Price Target	Buy	$45.00	Medium

(Data available from 8/12/2017 forward)

News Sentiment Rating

0.08 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

1 very positive mentions
9 positive mentions
0 negative mentions
1 very negative mentions

Mentions as of

1/14/2022

3 very positive mentions
7 positive mentions
2 negative mentions
1 very negative mentions

Mentions as of

2/13/2022

2 very positive mentions
5 positive mentions
1 negative mentions
1 very negative mentions

Mentions as of

3/15/2022

2 very positive mentions
2 positive mentions
1 negative mentions
0 very negative mentions

Mentions as of

4/14/2022

3 very positive mentions
13 positive mentions
0 negative mentions
2 very negative mentions

Mentions as of

5/14/2022

0 very positive mentions
5 positive mentions
0 negative mentions
1 very negative mentions

Mentions as of

6/13/2022

3 very positive mentions
7 positive mentions
1 negative mentions
1 very negative mentions

Mentions as of

7/13/2022

3 very positive mentions
20 positive mentions
8 negative mentions
0 very negative mentions

Mentions as of

8/12/2022

Current Sentiment

Recent Stories by Sentiment

Very Negative

No very negative mentions tracked during this time.

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX, a gene expression tests for breast, prostate, and colon cancers; Oncotype Test, a tissue test delivering tumor profiling to aid therapy selection for patients with advanced, metastatic, refractory, or recurrent cancer; Oncotype DX AR-V7 Nucleus Detect Test, a liquid-based test for advanced stage prostate cancer; Oncomap ExTra, that provides a complete biological picture of certain refractory, rare, or aggressive cancers; and Covid-19 testing services. The company's pipeline products focus on enhancing the Cologuard test's performance characteristics and developing blood and other fluid-based tests. It has license agreements with MAYO Foundation for Medical Education and Research; and Hologic, Inc. Exact Sciences Corporation was incorporated in 1995 and is headquartered in Madison, Wisconsin.

Today's Range

Now: $42.36

$42.07

$46.09

50 Day Range

MA: $44.06

$35.61

$49.49

52 Week Range

Now: $42.36

$35.34

$108.99

Volume

3,884,805 shs

Average Volume

2,129,417 shs

Market Capitalization

$7.50 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.32

Frequently Asked Questions

What sell-side analysts currently cover shares of Exact Sciences?: The following Wall Street analysts have issued reports on Exact Sciences in the last year: Benchmark Co., BTIG Research, Citigroup Inc., Cowen Inc, Cowen Inc., Craig Hallum, Evercore ISI, Piper Sandler, Raymond James, Robert W. Baird, StockNews.com, SVB Leerink LLC, The Goldman Sachs Group, Inc., and Wells Fargo & Company.
View the latest analyst ratings for EXAS.
What is the current price target for Exact Sciences?: 13 Wall Street analysts have set twelve-month price targets for Exact Sciences in the last year. Their average twelve-month price target is $71.00, suggesting a possible upside of 67.6%. SVB Leerink LLC has the highest price target set, predicting EXAS will reach $130.00 in the next twelve months. Piper Sandler has the lowest price target set, forecasting a price of $50.00 for Exact Sciences in the next year.
View the latest price targets for EXAS.
What is the current consensus analyst rating for Exact Sciences?: Exact Sciences currently has 3 hold ratings and 8 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe EXAS will outperform the market and that investors should add to their positions of Exact Sciences.
View the latest ratings for EXAS.
What other companies compete with Exact Sciences?: Other companies that are similar to Exact Sciences include Guardant Health, Natera, Quest Diagnostics, Laboratory Co. of America and DENTSPLY SIRONA. Learn More about companies similar to Exact Sciences.
How do I contact Exact Sciences' investor relations team?: Exact Sciences' physical mailing address is 5505 ENDEAVOR LANE, MADISON WI, 53719. The medical research company's listed phone number is (608) 284-5700 and its investor relations email address is [email protected] The official website for Exact Sciences is www.exactsciences.com. Learn More about contacing Exact Sciences investor relations.

NASDAQ:EXAS - Exact Sciences Stock Price Target and Predictions

Analyst Price Target for EXAS

Current Consensus is Buy

Past Monthly Recommendations

Latest Recommendations

News Sentiment Rating

0.08 (Hold)

News Sentiment Over Time

Current Sentiment

Recent Stories by Sentiment

Very Negative

Negative

Positive

Very Positive

Today's Range

50 Day Range

52 Week Range

Volume

Average Volume

Market Capitalization

P/E Ratio

Dividend Yield

Beta

Frequently Asked Questions

What sell-side analysts currently cover shares of Exact Sciences?

What is the current price target for Exact Sciences?

What is the current consensus analyst rating for Exact Sciences?

What other companies compete with Exact Sciences?

How do I contact Exact Sciences' investor relations team?